AREVA Med

decorative

About AREVA Med

AREVA Med is an AREVA subsidiary created in 2009 to develop innovative therapies to fight cancer.

decorative

Nuclear Medicine

Learn more about nuclear medicine and targeted alpha therapy (TAT) with lead-212, and about our ongoing research.

decorative

Clinical Trials

AREVA Med launched the first Phase 1 clinical trial of lead-212       (patient enrollment completed in 2014).

decorative

News & Materials

Read about the latest news and events, watch a video, or download our brochure.

decorative

Macrocyclics

Macrocyclics, an AREVA Med company, is the global leader in chelating agent technologies for medicine.

Latest News

Bpifrance to support AREVA Med and its partners in developing new lead-212 treatments for cancer

07/01/2015

Bpifrance to support AREVA Med and its partners in developing new lead-212 treatments for cancer

Read more
AREVA Med and RadioMedix partner to develop new treatment against Neuroendocrine Tumors

05/18/2015

AREVA Med and RadioMedix partner to develop new treatment against Neuroendocrine Tumors

Read more
AREVA Med Receives CEO Cancer Gold Standard Accreditation

03/17/2015

AREVA Med Receives CEO Cancer Gold Standard Accreditation

Read more
Contact

For more information about AREVA Med, please contact:
Alison Tise
Tel.: + 1 (301) 841-1673

Contact

For more information about Macrocyclics, please contact:

Garry Kiefer

Tel.: + 1 (972) 250-2248

CEO Cancer Gold Standard
decorative

AREVA Med receives CEO Cancer Gold Standard accreditation

Twitter
decorative

Follow @AREVAmed on

Linked In
decorative

Follow AREVA Med on